GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Cyclically Adjusted PS Ratio

Exagen (Exagen) Cyclically Adjusted PS Ratio : 0.43 (As of Jun. 08, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Exagen Cyclically Adjusted PS Ratio?

As of today (2024-06-08), Exagen's current share price is $2.02. Exagen's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was $4.68. Exagen's Cyclically Adjusted PS Ratio for today is 0.43.

The historical rank and industry rank for Exagen's Cyclically Adjusted PS Ratio or its related term are showing as below:

XGN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.34   Med: 0.46   Max: 0.68
Current: 0.43

During the past 11 years, Exagen's highest Cyclically Adjusted PS Ratio was 0.68. The lowest was 0.34. And the median was 0.46.

XGN's Cyclically Adjusted PS Ratio is ranked better than
88.55% of 131 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.5 vs XGN: 0.43

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exagen's adjusted revenue per share data of for the fiscal year that ended in Dec23 was $2.972. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.68 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exagen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Exagen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Cyclically Adjusted PS Ratio Chart

Exagen Annual Data
Trend Dec13 Dec14 Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.56 0.42

Exagen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.42 -

Competitive Comparison of Exagen's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Exagen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exagen's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exagen's Cyclically Adjusted PS Ratio falls into.



Exagen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Exagen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.02/4.68
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exagen's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Exagen's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=2.972/129.4194*129.4194
=2.972

Current CPI (Dec23) = 129.4194.

Exagen Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.524 98.326 0.690
201412 2.000 99.070 2.613
201512 3.078 99.792 3.992
201712 5.080 104.011 6.321
201812 5.563 105.998 6.792
201912 11.284 108.420 13.470
202012 3.323 109.897 3.913
202112 3.024 117.630 3.327
202212 2.667 125.222 2.756
202312 2.972 129.419 2.972

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exagen  (NAS:XGN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Exagen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Exagen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exagen (Exagen) Business Description

Traded in Other Exchanges
Address
1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Executives
John Aballi director, officer: President and CEO C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p. 10 percent owner 11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi officer: Chief Financial Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine officer: Chief Operating Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson director 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker director 441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes director C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack officer: Chief Medical Officer C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux officer: Chief Scientific Officer C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081